NutriBand Inc. (NTRB) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US67092M2089
NutriBand Inc. financials
| Fiscal year | 2025 | 2026 |
|---|---|---|
| Revenue | 2.14 m USD | 2.04 m USD |
| Gross profit | 743,317.00 USD | 566,308.00 USD |
| Operating income | -10.28 m USD | -8.32 m USD |
| EBIT | -10.65 m USD | -8.32 m USD |
| Net income | -10.48 m USD | -8.23 m USD |
| Diluted EPS – continuing operations | -0.99 USD | -2.58 USD |
Full history since 2016, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About NutriBand Inc.
Nutriband Inc. develops a portfolio of transdermal pharmaceutical products in the United States. Its lead product is AVERSA Fentanyl, an abuse deterrent fentanyl patch for the treatment of chronic pain. The company also develops AVERSA buprenorphine and AVERSA methylphenidate. It has a commercial development and clinical supply agreement for Aversa Fentanyl with Kindeva Drug Delivery. The company was incorporated in 2016 and is headquartered in Orlando, Florida.
More stocks
- FNS TECH. Co., Ltd (083500.KQ)
- Outset Medical, Inc. (OM)
- Libertas 7 SA (LIB.MC)
- Soonest Express Co Ltd (2643.TWO)
- Gigastone Corporation (5262.TWO)
- Integrated Logistics Bhd (5614.KL)
- Brazilian Critical Minerals Ltd (BCM.AX)
- International Media Acquisition Corp. (IMAQ)
- Anam Electroni (008700.KS)
- Unitech Electronics Co. Ltd. (3652.TW)
- Citba Financial Corp (CBAF)
- RoyalTek Co Ltd (3306.TWO)
Not investment advice. All data without warranty, price as of 12.11.2026. Details in the risk notice.